Lusutrombopag

芦曲泊帕

Report date: 2023/07/04 14:50:25
NME

Base Information

Drug NameLusutrombopag
Drug Alias Name卢舒琼珀MulpletaS-888711
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionThrombopoietin receptor agonists
TargetsThrombopoietin receptor
Therapy Area/IndicationsThrombocytopeniaPurpura, Thrombocytopenic, IdiopathicLiver Diseases
Global Approved IndicationsThrombocytopenia
Approved Indications in ChinaThrombocytopenia
Original Approved Country/TerritoryJapan
Original Approved Date2015/09/28
Country/TerritoryUnited StatesEUMainland China +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesShionogi & Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSuzhou Xikro Pharmaceutical Co LtdVancocin Italia SrlShionogi Bv +[4] 
Inactive CompaniesSuzhou Yiteng Pharmaceutical Sales Co Ltd
Active IndicationsThrombocytopenia
Inactive IndicationsPurpura, Thrombocytopenic, IdiopathicLiver Diseases

Other Information

ATC CodeB02BX07
Related LinksWikipediaDrugBankKEGG